Todd R MarcySummaryAffiliation: University of Oklahoma Health Sciences Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
Second-generation thiazolidinediones and hepatotoxicityTodd R Marcy
Department of Pharmacy, Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117 1223, USA
Ann Pharmacother 38:1419-23. 2004....
Antidepressant-induced sweatingTodd R Marcy
Department of Pharmacy Clinical and Administrative Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117 1223, USA
Ann Pharmacother 39:748-52. 2005..To report a case of excessive sweating probably caused by paroxetine, review the literature on antidepressant-induced sweating, and provide recommendations for the management of antidepressant-induced sweating...
Aldosterone antagonists in the treatment of heart failureTodd R Marcy
University of Oklahoma College of Pharmacy, Oklahoma City, OK 73190, USA
Am J Health Syst Pharm 63:49-58. 2006..The clinical benefits, adverse effects, pharmacokinetics, and recommendations for the appropriate use of the aldosterone antagonists spironolactone and eplerenone in patients with heart failure are reviewed...
Identification of barriers to appropriate dietary behavior in low-income patients with type 2 diabetes mellitusTodd R Marcy
Department of Pharmacy, Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy, 1110 N Stonewall, Oklahoma City, OK, 73117 1200, USA
Diabetes Ther 2:9-19. 2011..To identify barriers to appropriate dietary behavior in an urban, low-income population of patients with type 2 diabetes and to examine a new instrument in the identification of these barriers in this population...
Extended therapy for primary and secondary prevention of venous thromboembolismSusan E Conway
Department of Pharmacy Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Oklahoma City, OK 73126, USA
J Pharm Pract 23:313-23. 2010..The optimal duration of anticoagulation therapy for primary or secondary prevention of VTE should include the health care provider and patient making a decision based on evaluation of individual benefits, risks, and preferences...
